Should Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?

McIntyre, Roger S.; Soczynska, Joanna K.; Konarski, Jakub Z.; Woldeyohannes, Hanna O.; Law, Candy W. Y.; Miranda, Andrew; Fulgosi, Don; Kennedy, Sidney H.

doi:10.1080/10401230701653377

Cited by 217 publications

(170 citation statements)

References 77 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…It has been hypothesized that BD and metabolic syndrome share a set of common risk factors and overlapping pathophysiology 782, 783, 784. While medications used to treat BD, particularly atypical antipsychotics, can also lead to metabolic dysfunction and weight problems (Section 8), insufficient access to primary and preventative health care, low socioeconomic status, habitual inactivity, insulin dysfunction, peripheral inflammation and neuroinflammation, oxidative stress, and childhood adversity are also important contributors 785…”

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Depression has been likened to a state of ''accelerated aging,'' affecting the hippocampus and the cardiovascular (CV), cerebrovascular, neuroendocrine, metabolic, and immune systems, [1][2][3] and depressed individuals have a higher incidence of various diseases often associated with aging, such as Type II diabetes, metabolic syndrome, osteoporosis, CV disease, stroke, and pathological cognitive aging, including Alzheimer's disease and other dementias. [2,[4][5][6][7][8] Depression is also associated with significantly worse outcomes in a number of medical conditions, and depression is an independent risk factor for early mortality (even after accounting for sociodemographic factors, suicide, and biological and behavioral risk factors, such as smoking, alcohol, and physical illness).…”

mentioning

confidence: 99%

Depression gets old fast: do stress and depression accelerate cell aging?

et al. 2010

View full text Add to dashboard Cite

“…The mood improvements associated with weight loss may be attributable to reductions in pathophysiological processes such as inflammation and hypothalamic-pituitary-adrenal axis activation that are common to both insulin resistance and mood disorders. [7] We examined the predictors of weight change among participants at S1 using multivariable analysis (Table 3). We found that each visit per month increase in the LI was associated with a 0.7 kg/m 2 greater loss in BMI after controlling for sex, age, baseline BMI and time spent in the programme.…”

Section: Fig 1 Weight Loss (%) Among Participants In Lis In Two Primentioning

confidence: 99%

A successful lifestyle intervention model replicated in diverse clinical settings

Mark¹,

Toit²,

Noakes

et al. 2016

S Afr Med J

View full text Add to dashboard Cite

Lifestyle interventions (LIs) can treat metabolic syndrome and prevent type 2 diabetes mellitus, but they remain underutilised in routine practice. In 2010, an LI model was created in a rural primary care practice and spread with few resources to four other rural practices. A retrospective chart review evaluated changes in health indicators in two practice environments by following 372 participants, mainly women (mean age 52 years). Participants had a mean body mass index of 37 kg/m 2 at baseline and lost an average of 12% of their initial body weight as a result of the intervention. Among participants at the first intervention site for whom cardiometabolic data were available, the prevalence of metabolic syndrome decreased from 58% at baseline to 19% at follow-up. Taken as a whole, our experience suggests that LIs are feasible and deliver meaningful results in routine primary care practice.

show abstract

Should Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?

Cited by 217 publications

References 77 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Depression gets old fast: do stress and depression accelerate cell aging?

A successful lifestyle intervention model replicated in diverse clinical settings

Contact Info

Product

Resources

About